Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-054515
Filing Date
2024-05-07
Accepted
2024-05-07 16:15:55
Documents
60
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rptx-20240331.htm   iXBRL 10-Q 1456040
2 EX-10.1 rptx-ex10_1.htm EX-10.1 18001
3 EX-31.1 rptx-ex31_1.htm EX-31.1 15055
4 EX-31.2 rptx-ex31_2.htm EX-31.2 15024
5 EX-32.1 rptx-ex32_1.htm EX-32.1 12795
6 GRAPHIC img194139340_0.jpg GRAPHIC 79855
  Complete submission text file 0000950170-24-054515.txt   6709557

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rptx-20240331.xsd EX-101.SCH 943474
64 EXTRACTED XBRL INSTANCE DOCUMENT rptx-20240331_htm.xml XML 1172915
Mailing Address 7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9
Business Address 7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9 (857) 412-7018
Repare Therapeutics Inc. (Filer) CIK: 0001808158 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39335 | Film No.: 24922108
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)